Onconova Therapeutics Cash Flow - Annual (NASDAQ:ONTX)

Add to My Stocks
$0.5 $0.01 (2.04%) ONTX stock closing price Sep 18, 2018 (Closing)

The Onconova Therapeutics cash flow statement is one of the three reports that the company generates every quarter. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Onconova Therapeutics profits one has to check the income statement and for Onconova Therapeutics debt one has to check the balance sheet. Onconova Therapeutics cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Onconova Therapeutics had cash and cash equivalents of $21.45M at the beginning of the year and $4.02M at year end for 2017. ONTX decrease in investments stood at a value of $- for the latest year 2017.

View details of Onconova Therapeutics cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow-----8.51M-
Net Increase (Decrease) in Assets Liabilities-3.81M-11.17M--7.24M9.55M13.06M
Cash From (used in) Discontinued Operations-------
Other Adjustments Net--0.05M3.8M5.04M7.96M13.48M-1.28M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment----0.22M-0.6M-0.27M-0.25M
Acquisition Disposition of Subsidiaires-------
Increase (Decrease) in Investments---40M-39.99M--
Other Cash Inflow (Outflow) from Investment Activities-------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares6.36M17.42M7.46M-79.96M54.47M9.29M
Issuance (Repayment) of Debt Securities-----25.82M-0.29M
Increase (Decrease) in Bank & Other Borrowings-------
Payment of Dividends & Other Cash Distributions-------
Other Cash from (used by) Financing Activities------2.83M-
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash--0.01M-0.01M-0.01M---
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year21.45M19.79M43.58M60M81.52M2.71M7.34M
Cash & Equivalents at Year End4.02M21.4M19.79M43.58M60M81.52M2.71M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Celgene financial analysis

While Onconova Therapeutics stock price history provides the price history of a stock, Onconova Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Onconova Therapeutics is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Onconova Therapeutics stock price movement.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Onconova Therapeutics lost $-23.82M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $- for ONTX in last 2017 report.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $6.36M for Onconova Therapeutics.

Key Financial Ratios For Onconova Therapeutics Cash Flow